1. Adelaide Research & Scholarship

Search


Current filters:





Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 11-17 of 17 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsYeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Trotman, J.; Forsyth, C.; Taper, J.; Ross, D.; Beresford, J.; Tam, C.; et al.
2015Adjunctive raloxifene treatment improves attention and memory in men and women with schizophreniaWeickert, T.; Weinberg, D.; Lenroot, R.; Catts, S.; Wells, R.; Vercammen, A.; O'Donnell, M.; Galletly, C.; Liu, D.; Balzan, R.; Short, B.; Pellen, D.; Curtis, J.; Carr, V.; Kulkarni, J.; Schofield, P.; Weickert, C.
2010Apixaban for reduction in stroke and other ThromboemboLic events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleLopes, R.; Alexander, J.; Al-Khatib, S.; Ansell, J.; Diaz, R.; Easton, J.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Hylek, E.; McMurray, J.; Verheugt, F.; Wallentin, L.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2011Efficacy of α-lactalbumin and milk protein on weight loss and body composition during energy restrictionSoenen, S.; Hochstenbach-Waelen, A.; Westerterp-Plantenga, M.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.

Discover